1. Home
  2. POOL vs IONS Comparison

POOL vs IONS Comparison

Compare POOL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pool Corporation

POOL

Pool Corporation

HOLD

Current Price

$246.38

Market Cap

11.6B

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$81.52

Market Cap

12.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POOL
IONS
Founded
1993
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6B
12.3B
IPO Year
1995
1991

Fundamental Metrics

Financial Performance
Metric
POOL
IONS
Price
$246.38
$81.52
Analyst Decision
Hold
Strong Buy
Analyst Count
9
21
Target Price
$338.33
$80.71
AVG Volume (30 Days)
979.5K
3.1M
Earning Date
10-23-2025
10-29-2025
Dividend Yield
2.03%
N/A
EPS Growth
N/A
N/A
EPS
10.93
N/A
Revenue
$5,294,666,000.00
$966,957,000.00
Revenue This Year
$1.92
$27.96
Revenue Next Year
$3.55
$2.33
P/E Ratio
$22.55
N/A
Revenue Growth
N/A
20.41
52 Week Low
$229.63
$23.95
52 Week High
$380.82
$82.95

Technical Indicators

Market Signals
Indicator
POOL
IONS
Relative Strength Index (RSI) 41.99 67.63
Support Level $240.31 $71.83
Resistance Level $248.39 $82.95
Average True Range (ATR) 7.27 3.00
MACD 2.58 0.70
Stochastic Oscillator 65.19 90.22

Price Performance

Historical Comparison
POOL
IONS

About POOL Pool Corporation

Pool Corp distributes swimming pool supplies and related products. Its products include non-discretionary pool-maintenance products, like chemicals and replacement parts, as well as pool equipment, like packaged pools (kits to build swimming pools), cleaners, filters, heaters, pumps, and lights. Customers include pool builders and remodelers, independent retail stores, and pool repair and service companies.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.

Share on Social Networks: